Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction (MI) in rheumatoid arthritis. C–reactive protein (CRP) was associated with risk of MI and the results underline the importance of tight disease control taking not only global disease activity, but also CRP as an individual marker into account. Bio Med Central, Arthritis Research & Therapy, 08/05/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis and DMARDs)
Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single–center experience. Myelitis is associated with a significant increase in accrual damage compared with severe non–neuropsychiatric manifestations. PubMed, Lupus, 08/01/2016. (Also see Symptoms and Complications of Lupus)
End Stage Renal Disease (ESRD) in Patients with Rheumatoid Arthritis. Physicians should be aware of the critical impact of the comorbidities of diabetes and hypertension in causing ESRD in RA patients. Seminars in Arthritis and Rheumatism, 07/16/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis)
A new approach to the improvement of quality of life in fibromyalgia (FMS): a pilot study on the effects of an aquatic Ai Chi program. A water–based Ai Chi program may contribute to the improvement of mental and physical health and the quality of life in women with FMS. PubMed, Int J Rheum Dis, 07/26/2016. (Also see Treatments for Fibromyalgia)
‘Generic’ Biologic Drugs Appear Comparable to Brand–Name Counterparts. New analysis suggests common and costly medications made from living cells can be equivalent even when manufactured by different company. Johns Hopkins News Release, 08/01/2016. (Also see Biologic Agents)
National trends and in–hospital outcomes in patients with rheumatoid arthritis (RA) undergoing elective atlantoaxial spinal fusion (AASF) surgery. In–hospital morbidity and mortality rates of AASF in RA patients were higher than those of other major orthopaedic surgeries in RA patients and respiratory management is particularly important after AASF. PubMed, Clin Exp Rheumatol, 07/26/2016. (Also see Treatments for Rheumatoid Arthritis)
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation (ASCT). The study found significant differences in the OS depending on when the acute renal failure occurred and patients who required dialysis within 30 days of ASCT had the highest rate of treatment–related mortality. PubMed, Nephrol Dial Transplant, 2016 Aug;31(8):1284-9. (Also see Stem Cell (Bone Marrow) Transplantation)
Prevalence of cardiovascular–related (CVD) comorbidity in ankylosing spondylitis (AS), psoriatic arthritis (PsA) and psoriasis (Ps) in primary care: a matched retrospective cohort study. Our findings provide UK comparisons of CVD–related comorbidities in patients with AS, PsA and Ps alone, which further supports the argument for more evidence in the need for screening and intervention around CVD comorbidities in inflammatory conditions. PubMed, Clin Rheumatol, 08/02/2016. (Also see Ankylosing Spondylitis and Psoriasis and Psoriatic Arthritis)
Resistance exercise improves physical fatigue in women with fibromyalgia: a randomized controlled trial. Person–centered progressive resistance exercise improved physical fatigue in women with FM when compared to an active control group. Bio Med Central, Arthritis Research & Therapy, 07/30/2016. (Also see Treatments for Fibromyalgia)
Rituximab usage in systemic lupus erythematosus (SLE)–associated antiphospholipid syndrome (APS): A single–center experience. In this single–center study there were no recurrent thrombotic events after the rituximab therapy, implicating further consideration of large–scale trials to evaluate its therapeutic role in SLE–associated APS patients. PubMed, Semin Arthritis Rheum, 2016 Aug;46(1):102-8. (Also see Treatments for Lupus and Antiphospholipid Syndrome)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: